An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens. (Q53811493)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens. |
scientific article |
Statements
An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens. (English)
Giovanni Scambia
Nicoletta Colombo
Gabriella Parma
Rosanna Mancari
Gianluca Del Conte
Dagmar Hess
Dionyssios Katsaros
Cristiana Sessa
Andrea Rinaldi
Andrea Vitali
Carlo Vittorio Catapano
Helgi van de Velde
1 June 2012
22
5
792-800